Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GEM21menos65. A Phase III Trial for NDMM Patients Who Are Candidates for ASCT Comparing Extended VRD Plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D

NCT05558319 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT05558319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05558319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GEM21menos65. A Phase III Trial for NDMM Patients Who Are Candidates for ASCT Comparing Extended VRD Plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D
Lead sponsor
PETHEMA Foundation
Phase
Phase 3
Overall status
Recruiting
Start date
November 10, 2022
Completion date
April 30, 2029
Enrollment
480 (estimated)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed multiple myeloma